Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics Inc (RLMD)
:RLMD
RESEARCH TOOLSreports
Holding RLMD?
Track your performance easily
Earnings Data
Report Date
Mar 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.71Last Year’s EPS
-0.84Same Quarter Last Year
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 12, 2021
|% Change Since: -88.65%
|Next Earnings Date:Mar 23, 2021
Earnings Call Sentiment|Neutral
The earnings call highlighted ongoing progress in clinical trials for REL-1017 and the psilocybin-based program, which are viewed as potential derisking events. However, the company's financials show an increased cash burn and ongoing net losses, balancing the positive clinical developments.Company Guidance
During the Relmada Therapeutics Q3 2024 earnings call, key guidance was provided around the company's priority to advance its CNS disorder treatments, particularly focusing on the Phase III program for REL-1017. The company anticipates results from the interim analysis of the Reliance II Phase III study by year-end 2024, which is expected to be a pivotal derisking event. The outcomes of this analysis could lead to one of three scenarios: continuing with the planned number of patients, increasing the sample size due to promising efficacy signals, or halting the study if deemed futile with a drug-placebo delta below approximately 2 points. Financially, Relmada reported cash and short-term investments of $54.1 million as of September 30, 2024, with cash used in operations at $16.7 million for the quarter. The net loss for Q3 2024 was $21.7 million, translating to a loss of $0.72 per share, with the company maintaining 30.2 million common shares outstanding.Progress on REL-1017 Program
The company is on track to report the outcome of an interim analysis for the REL-1017 Reliance II Phase III study by year-end 2024. This could be a significant derisking event for the study and the REL-1017 program.
Psilocybin-Based Metabolic Disease Program
The Phase I safety study for REL-P11 is screening subjects, and the first randomization is expected soon. The study will help define the pharmacokinetic safety and tolerability profile for a single dose of REL-P11.
Financial Position and Cash Flow
Relmada had cash, cash equivalents, and short-term investments of approximately $54.1 million as of September 30, 2024. The current cash position is expected to support operations through key near-term milestones into 2025.
---
RLMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RLMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $3.26 | $3.28 | +0.61% |
| Aug 07, 2024 | $3.24 | $2.30 | -29.01% |
| May 08, 2024 | $3.83 | $3.80 | -0.78% |
| Mar 19, 2024 | $5.37 | $4.44 | -17.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Relmada Therapeutics Inc (RLMD) report earnings?
Relmada Therapeutics Inc (RLMD) is schdueled to report earning on Mar 25, 2025, TBA Not Confirmed.
What is Relmada Therapeutics Inc (RLMD) earnings time?
Relmada Therapeutics Inc (RLMD) earnings time is at Mar 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RLMD EPS forecast?
RLMD EPS forecast for the fiscal quarter 2024 (Q4) is -0.71.
---